Comparative Safety Analysis of Anti-IL-4/IL-13 Inhibitors and JAK Inhibitors in Atopic Dermatitis
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
eText 1: ICD-10 Code Lists for Outcomes
应用场景：
创建时间：
2024-06-28
相关数据集
Table8_Anti-inflammatory and immunomodulatory effects of polysaccharide extracted from Wuguchong (maggot) on 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice.XLSX
Atopic dermatitis (AD) is an inflammatory, heterogeneous, chronic skin disorder characterized by recurrent eczematous lesions and intense pruritus, and the pathophysiology mechanism of AD is known for
NIAID Data Ecosystem180
Table_3_The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis.docx
BackgroundSeveral clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis (AD). Howeve
NIAID Data Ecosystem60
Data publication: Synthesis and preclinical evaluation of FAP-targeting radio...
Analytical data for chemical synthesis (HPLC, NMR, HRMS), biological data for in vitro and in vivo evaluation (binding assays, small animal imaging)
B2FIND50
Table S1 - Supplemental material for Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review
Supplemental material, Table S1, for Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review by Edgar Akuffo-Addo, Mathew N. Nicholas and Perla L
DataCite Commons2024-08-28 更新150
Full-text articles assessed for eligibility.
Background The newly approved biologics and Janus kinase inhibitors (JAKi) for pediatric atopic dermatitis (AD) offer additional options for clinical treatment. However, the efficacy and safety differ
NIAID Data Ecosystem50
